Proposed Cannabis Reclassification in the United States\n\nPresident Donald Trump is anticipated to sign an executive order to reclassify cannabis, a move that would represent a notable adjustment in US drug policy. The expected order would shift cannabis from its current classification as a Schedule I narcotic to a Schedule III drug.\n\nCurrent and Proposed Classifications\n\nSince 1971, cannabis has been categorized as a Schedule I narcotic, indicating that it lacks accepted medical use and possesses a high potential for abuse. A reclassification to Schedule III would place it alongside substances such as Tylenol with codeine, ketamine, and anabolic steroids, which the US Drug Enforcement Agency (DEA) defines as having only a moderate to low potential for physical and psychological dependence.\n\nPotential Impacts of Reclassification\n\nWhile cannabis would remain illegal at the federal level, a Schedule III designation could facilitate expanded research into its potential medical benefits. Additionally, the new classification may affect tax regulations for state-authorized cannabis dispensaries, which are currently restricted from certain tax deductions due to selling Schedule I products. Reports from various US news outlets suggest the announcement might also include a pilot program to reimburse some older Americans for cannabidiol (CBD) for conditions such as cancer treatment.\n\nBackground and State Landscape\n\nA majority of US states have approved cannabis for medical use, and 24 states have legalized recreational use. President Trump has stated his consideration for reclassification is based on the need for "tremendous amounts of research that can't be done unless you reclassify." He has previously advocated for ending arrests for personal marijuana use and implementing regulated access to tested products. A similar reclassification proposed by the Biden administration in April 2024 encountered administrative and legal obstacles.\n\nCongressional Reactions\n\nThe proposed reclassification has met with opposition from some Republican lawmakers. A group of 22 Republican Senators sent an open letter to the president, expressing concerns that such a move could normalize cannabis use and hinder efforts to "re-industrialise America." They cited research linking cannabis to "impaired judgement" and "lack of concentration" and argued against facilitating the growth of the marijuana industry due to documented health concerns.\n\nSeparately, in August, nine Republican representatives wrote to Attorney General Pam Bondi, asserting a lack of adequate scientific data to support the change. Their letter stated that marijuana, despite differing from heroin, retains potential for abuse and lacks scientifically proven medical value, warning that rescheduling could imply safety to children.\n\nPublic Opinion\n\nPublic opinion polls indicate broad support for cannabis legalization in the United States. A Gallup poll conducted in November found that 64% of Americans believe marijuana should be legalized, though support among Republicans showed a 13-point decrease compared to previous years.